Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

Keyphrases

• Type 2 Diabetic Patients 100%
• Glycemic Control 100%
• Rosiglitazone 100%
• Sulfonylurea Therapy 100%
• Sulfonylurea 71%
• Fasting Plasma Glucose 42%
• Hemoglobin A1c (HbA1c) 42%
• Placebo 28%
• LDL Cholesterol 28%
• Twice Daily 14%
• Treatment Group 14%
• C-peptide 14%
• Lipids 14%
• Insulin 14%
• Intention-to-treat Analysis 14%
• Hepatotoxicity 14%
• Hypoglycemia 14%
• Albumin 14%
• Gamma-glutamyltransferase 14%
• Cardiac Events 14%
• Gliclazide 14%
• Glibenclamide 14%
• Insulin Sensitizers 14%
• Thiazolidinediones 14%
• Non-esterified Fatty Acids 14%
• Glimepiride 14%
• Glipizide 14%

INIS

• doses 100%
• patients 100%
• therapy 100%
• control 100%
• glucose 50%
• plasma 50%
• fasting 50%
• hemoglobin 50%
• safety 33%
• insulin 33%
• cholesterol 33%
• levels 16%
• comparative evaluations 16%
• males 16%
• fatty acids 16%
• lipids 16%
• peptides 16%
• albumins 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Diabetes Mellitus 100%
• Sulfonylurea 100%
• Rosiglitazone 100%
• Hemoglobin A 42%
• Placebo 28%
• Fatty Acid 14%
• Low Density Lipoprotein Cholesterol 14%
• High Density Lipoprotein Cholesterol 14%
• Hepatotoxicity 14%
• Hypoglycemia 14%
• Glibenclamide 14%
• Thiazolidinedione 14%
• Gamma Glutamyltransferase 14%
• Glimepiride 14%
• C Peptide 14%
• Gliclazide 14%
• Glipizide 14%
• Carbutamide 14%
• Non Insulin Dependent Diabetes Mellitus 14%